PharmaCyte increases TNF Pharmaceuticals stake by $3 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
September 2, 2025 9:20 AM EDTTNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartners 2025 Hype Cycle for Data Center Infrastructure Technologies
LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNFA, TNF) by an additional $3 million. The Company does so to help support TNFs recent acquisition of a license with LightSolver, Ltd. (LightSolver), a company recognized by Gartner and the World Economic Forum for its breakthrough innovations. The license is for its revolutionary processing... More
